Clinical Trial Update: Suppression of Oral HHV8 Shedding With Valganciclovir [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating valganciclovir for suppression of oral shedding of human herpesvirus 8. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Herpesvirus Infection

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: University of Washington | Conditions: Human Herpesvirus 8 | Phase 2 | Status: COMPLETED